743 related articles for article (PubMed ID: 8555803)
1. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
2. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
[TBL] [Abstract][Full Text] [Related]
4. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
[TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Lees AJ; Katzenschlager R; Head J; Ben-Shlomo Y
Neurology; 2001 Nov; 57(9):1687-94. PubMed ID: 11706112
[TBL] [Abstract][Full Text] [Related]
6. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
7. Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Mizuno Y; Kondo T
Drug Saf; 1997 May; 16(5):289-94. PubMed ID: 9187529
[TBL] [Abstract][Full Text] [Related]
8. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
9. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH; Myllylä V
Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
[TBL] [Abstract][Full Text] [Related]
10. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
11. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
12. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
Przuntek H; Conrad B; Dichgans J; Kraus PH; Krauseneck P; Pergande G; Rinne U; Schimrigk K; Schnitker J; Vogel HP
Eur J Neurol; 1999 Mar; 6(2):141-50. PubMed ID: 10053226
[TBL] [Abstract][Full Text] [Related]
13. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
Myllylä VV; Sotaniemi KA; Hakulinen P; Mäki-Ikola O; Heinonen EH
Acta Neurol Scand; 1997 Apr; 95(4):211-8. PubMed ID: 9150811
[TBL] [Abstract][Full Text] [Related]
14. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
16. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the treatment of Parkinson's disease.
Hely MA; Morris JG
Curr Opin Neurol; 1996 Aug; 9(4):308-13. PubMed ID: 8858190
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
[TBL] [Abstract][Full Text] [Related]
19. Strategies in the treatment of early Parkinson's disease.
Rinne UK
Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
